NK Science
Why NK Cells Are Becoming Central to the Next Wave of Cell Therapy
Read insight
Investigational Platform · Immuno-Oncology
Engineering the Next Frontier of NK Cell Immunotherapy
BioNK is developing investigational NK and CAR-NK cell therapy platforms designed to address high-need oncology indications through scalable biology, translational discipline, and regulatory-ready development.
BioNK programs are investigational and subject to applicable regulatory, ethics, CMC, nonclinical and clinical validation requirements.
Why NK Cells
Innate immunity, engineered for translation.
Natural killer cells are part of the innate immune system. They recognize stressed or malignant cells through a balance of activating and inhibitory signals — without requiring prior antigen sensitization.
NK-based approaches are being explored for off-the-shelf cell therapy strategies, combination immunotherapy, and CAR-engineered platforms designed to extend tumor recognition while preserving favorable safety profiles.
The science behind NKThe BioNK Platform
Three integrated pillars for NK cell therapy translation.
01 // UNMODIFIED
Unmodified NK Cell Therapy
Investigational allogeneic NK cell approaches derived from cord blood and CD34+ progenitor biology, designed for off-the-shelf readiness.
02 // ENGINEERED
CAR-NK Engineering
Engineered NK cell programs designed to improve tumor targeting while leveraging the cytotoxic biology and safety profile of NK cells.
03 // TRANSLATIONAL
Translational & Regulatory
CMC, potency, comparability, cryopreservation, logistics, clinical strategy, and regulatory planning integrated from the earliest stages.
Strategic Indication
Initial Focus:
Ovarian Cancer
BioNK is evaluating RNK001 and CAR-NK development paths for recurrent or difficult-to-treat ovarian cancer settings, subject to regulatory, ethics and clinical validation requirements.
Future expansion is planned across selected hematologic and solid tumor indications, prioritized by biology, unmet need, manufacturability, regulatory feasibility and translational logic.
View pipelineRNK001
Allogeneic unmodified NK · Translational planning
CAR-NK Ovarian
Engineered CAR-NK · Preclinical / translational
NK / CAR-NK Expansion
Selected solid & hematologic indications · Discovery
Built for Regulated Translation
From target biology to regulated advanced therapy.
01
Target Biology
02
Cell Source
03
Expansion / Engineering
04
Potency & Release
05
Cryopreservation
06
Clinical Evaluation
07
Regulatory Strategy
08
Access Planning
Brazil & Latin America
A cell therapy bridge between global science and Latin America.
BioNK aims to connect global NK and CAR-NK science with Brazilian clinical, regulatory, manufacturing, and public-health infrastructure — including access to cryopreservation and logistics capabilities through the Cryopraxis ecosystem, subject to applicable quality agreements and project-specific validation.
Our strategy is designed to position Brazil as a credible participant in the global advanced therapy ecosystem, while reducing dependency on imported high-cost cell therapies.
Brazil & LatAm strategyPartnering
Collaborate at the interface of NK biology, CMC, and clinical translation.
BioNK works with academic, biotech, pharma, clinical, and public-health partners across NK / CAR-NK platform development, target validation, manufacturing, regulatory and market-access strategy.
Latest Insights
Scientific perspectives
Engineering
CAR-NK and CAR-T: Distinct Biology, Distinct Development Challenges
Read insight
Indication
Ovarian Cancer as a Strategic Test Case for NK Cell Therapy
Read insight
Brazil
Building Advanced Therapy Capacity in Brazil
Read insight